New genetic finding provides clue for personalizing depression treatment

A team of scientists at the Medical University of South Carolina (MUSC) has identified a stress-regulated gene that plays a role in the link between long-term stress and a common type of depressive behavior in mice. Specifically, this gene was needed for long-term stress to produce a loss of interest in activities that were once rewarding or pleasurable – often called anhedonia. However, the gene did not play a role in other common depressive-like symptoms, such as social avoidance and increased anxiety-like behavior. The team reported its findings recently in eLife.

The study was led by neuroscientists Makoto Taniguchi, Ph.D., and Christopher Cowan, Ph.D., and also Brandon Hughes, Ph.D., who was at the time of the study a graduate student in Neuroscience at MUSC and is now a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai.

The finding that the genetic pathway affected only one type of depressive behavior could have implications for how we treat depression, said Taniguchi.

“If we can find the individual mechanisms for the different symptoms, we can target these symptoms specifically in future therapeutic strategies,” he said.

Not everyone with long-term stress develops depression, explained Cowan, chair of the MUSC Department of Neuroscience, scientific council member of the Brain & Behavior Research Foundation and close collaborator of Taniguchi.  

“Many individuals can rebound from chronic stress,” he said.

However, some people who experience repeated stress develop depressive symptoms. Understanding how stress and depression are connected in the brain can help us to develop better treatments for people with mental health disorders.

How stress affects the brain

Taniguchi leads a lab in the Department of Neuroscience that is examining the relationship between stress and depression in the brain. In mice, long-term stress decreases functioning in the front part of the brain, he said. People with major depressive disorder often have reduced brain activity in the same part of the brain. Scientists have long thought that this loss of brain activity in the frontal part of the brain contributes to the symptoms of depression.  

Taniguchi and Cowan wondered whether there could be an important intermediary linking long-term stress to the development of depressive behavior.

They knew the gene NPAS4 was involved in the functioning of a portion of the brain called the prefrontal cortex. They also knew it acted as a “master regulator,” meaning that it could change the way many genes are expressed based on brain activity.

Exposing mice to stress triggers NPAS4 in the prefrontal cortex. In turn, NPAS4 changes gene expression and reduces functioning of this important reward-linked brain region. This change in gene expression is also seen in the brains of people with mental health disorders, such as depression.

The research team speculated that NPAS4 might play a crucial role in linking long-term stress with depression-like behaviors.

To test this hypothesis, the team manipulated NPAS4 in stressed mice and watched how they behaved. Surprisingly, NPAS4 did not affect all depressive behaviors –only the loss of interest in pleasurable activities. NPAS4 was not involved in either social avoidance or anxiety-like behaviors.

One size does not fit all

The team’s findings suggest that there is not one central mechanism by which stress causes the varied symptoms of depression. Instead, multiple pathways could connect stress with different types of symptoms.  

Diagnostic manuals list a variety of different depressive symptoms, including loss of energy, problems with sleep and difficulty concentrating. However, most patients with major depressive disorder develop only some of the common symptoms. Put another way, depression is not “one size fits all.”

The study’s findings, which identify a new brain mechanism associated with a single depressive-like symptom, support the idea of treating mental health disorders at the symptom- rather than diagnosis-level. They also suggest that effective treatments might need to target distinct brain mechanisms.

“I'm excited about the idea that we can start to focus in on individual symptoms,” said Cowan.

Cowan explained that some depressive symptoms can also be experienced by people with other mental health disorders, such as anxiety disorders, substance use disorder and schizophrenia.

Targeting specific symptoms could be a way to offer more effective, personalized treatments. For example, transcranial magnetic stimulation (TMS) is a noninvasive treatment for people with depression that is typically used when other treatments have not been effective. During TMS, an electronic magnetic coil is placed near an individual’s forehead, and the magnetic fields stimulate nerve cells in the brain. This study’s findings can help to inform how to target more effectively the parts of the brain that are most relevant to the symptoms someone is experiencing.  

“Depression is a mixed thing – different symptoms emerge in different individuals,” said Cowan. “Understanding the brain mechanisms underlying the varied symptoms, and recognizing that they are potentially distinct, is likely to pave the way for precision medicine approaches to treat specific symptoms in individuals struggling with mental health disorders.”   

# # #

Pilot funding from the South Carolina Clinical & Translational Research Institute helped to support early stages of this work, as well as a National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Grant from the Brain & Behavior Research Foundation.

About MUSC

Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,000 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy – and trains more than 850 residents and fellows in its health system. MUSC brought in more than $297.8 million in research funds in fiscal year 2022, leading the state overall in research funding. For information on academic programs, visit musc.edu.

As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 14 hospitals with approximately 2,500 beds and five additional hospital locations in development, more than 350 telehealth sites and connectivity to patients’ homes, and nearly 750 care locations situated in all regions of South Carolina. In 2022, for the eighth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

MUSC and its affiliates have collective annual budgets of $5.1 billion. The nearly 25,000 MUSC team members include world-class faculty, physicians, specialty providers, scientists, students, affiliates and care team members who deliver groundbreaking education, research and patient care.

About the SCTR Institute

The South Carolina Clinical & Translational Research (SCTR) Institute is the catalyst for changing the culture of biomedical research, facilitating the sharing of resources and expertise and streamlining research-related processes to bring about large-scale change in clinical and translational research efforts in South Carolina. Our vision is to improve health outcomes and quality of life for the population through discoveries translated into evidence-based practice. To learn more, visit https://research.musc.edu/resources/sctr.